Danish pharmaceutical manufacturer Novo Nordisk on Dec. 22 announced that the U.S. Food and Drug Administration (FDA) has ...

Expanded use of GLP-1 drugs may lead to more side effects, already the subject of thousands of lawsuits now moving through ...

A growing body of research and experts have suggested that GLP-1s can be powerful tools for midlife women. Here’s what we ...

A systematic review and meta-analysis evaluated the risk for obesity-related cancer associated with glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with type 2 diabetes (T2D) or ...

Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) may protect against vertebral fractures in people with diabetes, ...

The FDA has approved the first oral glucagon-like peptide-1 (GLP-1) receptor agonist for weight loss and to reduce the risk of major adverse cardiovascular events (MACE). 1 Novo Nordisk plans to ...

After ushering in a new era of obesity treatment with its GLP-1 medicine Wegovy earlier in the decade, Novo Nordisk is making ...

Based Probiotic Category Ahead of 2026 Weight-Loss Season – Ingredient Research, Regulatory Context, and Evidence Gaps ...

Meanwhile, people with overweight or obesity lost up to 11.3% more weight than placebo by week 36 with a novel GLP-1 agonist ...

Below is a comparison of today’s most prescribed GLP-1 medications, including Ozempic and Trulicity, both widely used for ...

A recent study found that Glucagon-like peptide-1 (GLP-1) receptor agonist use in hypertrophic cardiomyopathy (HCM) patients ...

GLP-1 receptor agonists were tied to a 16% lower risk of epilepsy in adults with type 2 diabetes. Epilepsy is an ...